ARGX-111 is a defucosylated anti-MET antibody that inhibits both HGF-dependent and HGF-independent signaling and reduces MET expression on tumor cell surfaces. It suppresses tumor metastasis by enhancing antibody-dependent cellular cytotoxicity (ADCC) to deplete MET-expressing circulating tumor cells. In metastatic breast cancer orthotopic mouse models, ARGX-111 has been shown to deplete circulating tumor cells and inhibit bone and lung metastases. This compound is suitable for research in cancers such as breast cancer.
Target:
c-Met/HGFR
* VAT and and shipping costs not included. Errors and price changes excepted
